Lynda Charters

Trial shows treatment has acceptable safety profile, may improve visual function.

AAO develops task forces to evaluate academy, review outcomes in ophthalmology.

Physicians should hospitalize ON patients to prevent blindness, possible death.

Structural photoreceptor abnormalities and an area of central sparing found.

Deep learning predictions of the retinal nerve fiber layer thickness based solely on fundus photographs can be used to monitor the risk of future glaucomatous conversion in glaucoma suspects.

Clues to diagnosis from patient and family histories, examination techniques.

In a study, a single intravitreal injection of ADVM-022 had a 99% reduction in the mean annualized frequency of anti-VEGF injections.

Investigators corroborate the hypothesis that retinal ganglion cells with dendrites stratified in the off sublaminae could be damaged.

In endophthalmitis, the systemic anti-infective treatment specific to the infectious agent should always be used.

Amid pandemic, physicians and patients have embraced remote technology.

Measures of inflammation can predict treatment outcomes for patients

An updated PDS procedure reduces complications.

RGX-314 eyed by investigators as a therapeutic option for exudative AMD.

Preexisting neutralizing antibodies associated with the inflammatory changes.

Investigators at Mount Sinai report that ocular cells may be infected directly by the virus, with the limbus especially susceptible.

Study results show that aflibercept-treated eyes are protected.

Study results show the device offers an effective long-term option for patients.

Mark Pennesi, MD, PhD, reports during ARVO 2021 that preliminary results have shown that AGTC-401 and AGTC-402 seem safe and well tolerated in patients with ACHM.

In a presentation at ARVO, Friederike Kortuem, MD, MSc, explains that treatment with voretigene neparvovec-rzyl led to a short-term change in the foveal morphology in a patient with visual impairment that included nyctalopia and decreased visual acuity in early childhood.

Clinicians' knowledge of the epidemiology, natural history, causal mechanisms, and treatments for diabetic retinopathy (DR) has evolved dramatically over recent decades.

In a clinical trial, investigators used an adeno-associated viral vector to deliver a normal functioning copy of the RPGR gene via subretinal injection.

EYS809, a non-viral gene therapy sustained drug-delivery product that delivers anti-vascular endothelial growth factor to the eye, may replace the need for repeated intravitreal anti-VEGF injections and improve vision in patients diagnosed with wet age-related macular degeneration.

Logan Vander Woude, DO, MPH, examines research on improved resolution of symptomatic vitreomacular traction as an attempt to further refine the potential factors predictive of better outcomes.

Robyn Guymer, PhD, MBBS, highlights the latest trial results for faricimab, the first bispecific antibody designed for intraocular use in treating patients with neovascular age-related macular degeneration.

Sunil Srivastava, MD, examines why and how optical coherence tomography characteristics may be predictive of the efficacy of the injections.

Bryce Buchowicz, MD, outlines roadblocks to timely diagnosis of central retinal artery occlusion and treatment with tissue plasminogen activator during a virtual presentation at ARVO.

Logan Vander Woude, DO, MPH, takes a deeper dive into symptomatic vitreomacular traction research in an attempt to further refine the potential factors predictive of better outcomes.

Investigators offer insight on how patients with BRVO or CRVO with any lapse in treatment of 3 months or longer are at risk for poorer outcomes.

John Wells, MD, presents efficacy, durability, and safety findings from phase 3 YOSEMITE and RHINE trials during the virtual ARVO meeting.

Community support and research continue to boost treatment in children